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http://dx.doi.org/10.1016/j.jacl.2015.09BACKGROUND: Statins have demonstrated significant benefit in reducing cardiovascular disease
(CVD) risk.
OBJECTIVE: To evaluate statin treatment patterns by intensity, elevated low-density lipoprotein
cholesterol (LDL-C) levels, and cardiovascular (CV) events in high-risk CVD patients.
METHODS: Patients included were aged$18 years, with a coronary heart disease (CHD; Jan 1, 2007–
Dec 31, 2011, index date) or CHD risk equivalent (CHD RE) diagnosis (Jan 1, 2007–Dec 31, 2010, index
date), in the TruvenMarketScan claims database, continuously enrolled for 2 years pre- and up to 1 (CHD)
or 2 (CHDRE) years post-index. Patients with CHD, CHDRE, rhabdomyolysis, or chronic kidney disease
any time pre-indexwere excluded. Statin therapywas assessed at baseline, 30, 90, and 365 days post-index.
LDL-C valueswere captured in patientswith available data at 30-day intervals up to 1 year. CVevents were
evaluated up to 1 year post-index. Descriptive statistics were used to report results.
RESULTS: There were 175,103 CHD and 68,290 CHD RE patients; 3333 CHD RE patients had post-
index CVevents. At 1 year, 38.7% of CHD patients and 44.3% of CHD RE patients with post-index CV
events were not prescribed statins. Most patients who were prescribed statins, received a moderate-
intensity statin. The percentage of patients with LDL-C $ 100 mg/dL reduced over time, but at 1 year,
29.3% of CHD and 30.0% of CHD RE patients with post-index CV events had LDL-C $ 100 mg/dL.
At 1 year post-index, 9.9% CHD and 7.3% CHD RE patients had at least 1 CVevent.
CONCLUSION: There is room for better LDL-Cmanagement among high-risk CVD patients to reduce
their overall CV risk.
 2016 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).erapy Outcomes Research Center,
h, 30 South 2000 East, Rm 4858,
.utah.edu
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.008Introduction
Cardiovascular disease (CVD) is the leading cause of
mortality in the United States with 235.5 deaths per
100,000 with coronary heart disease (CHD) alone respon-
sible for nearly 1 of every 6 deaths in 2010.1 A major riskhis is an open access article under the CC BY-NC-ND license (http://
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terol (LDL-C).2 Various therapeutic interventions to lower
elevated LDL-C such as statins and ezetimibe have shown
that decreasing LDL-C levels significantly reduces CVD
events.3–8
Patients with established CHD and CHD risk equivalent
(CHD RE) indications have a high risk of subsequent CV
events including myocardial infarction (MI), stroke, and
death, and statins have been recommended as the first choice
of treatment in these patients to reduce CVD events.9
However, statins also have their challenges with several
studies indicating suboptimal use in high-risk patients,10–14
elevated LDL-C levels in spite of statin use,15 and the issue
of residual CVD risk in patients even with high-intensity
statin treatment.16–19
The National Cholesterol Education Program Adult
Treatment Panel III (ATP III) guidelines considered patients
with CHD or a CHD RE diagnosis to be high-risk patients
and recommended an LDL-C goal of ,100 mg/dL.20 This
LDL-C treatment goal was also supported by the 2015 Na-
tional Lipid Association (NLA) treatment recommendations
for patient-centered management of dyslipidemia among pa-
tients with low, moderate, or high atherosclerotic CVD
(ASCVD) risk.21 The 2013 American College of Cardiology
(ACC)/American Heart Association (AHA) cholesterol
guidelines advocated the use of risk appropriate statin inten-
sity (and adjuvant lipid-modifying therapy as indicated) to
optimally reduce risk for CV events.22
The objective of our study was to evaluate real-world
statin treatment patterns using the 2013 ACC/AHA defini-
tions for statin intensity, NLA 2015/ATP III recommended
goal attainment of LDL-C , 100 mg/dL, and CV events
among high-risk CHD and CHD RE patients.Materials and methods
Study design
This retrospective cohort study used Truven Health
‘‘MarketScan’’ Research Database. This widely published
commercial database23,24 contains combined medical and
pharmacy claims from approximately 40 employers, and
a number of health plans representing over 35 million
covered lives in 2008. The study period was from January
1, 2005 through December 31, 2012. Please refer to the
Supplementary Data section for more information
regarding Truven Health MarketScan Research Database.Study population
The study sample (Fig. 1) included patients aged 18 years
and older with a diagnosis of hyperlipidemia as per ‘‘Inter-
national Classification of Diseases, 9th Revision’’ (ICD-9)
diagnosis codes 272.0-272.4 and/or a claim for a statin
and were categorized into two cohorts. Patients with ICD-9 or ‘‘Current Procedural Terminology’’ codes (Table 1 in
Supplementary Data) for CHD (MI, unstable or stable
angina, coronary artery bypass graft, or percutaneous coro-
nary intervention) between January 1, 2007 and December
31, 2011 were categorized as the CHD cohort. Patients
with ICD-9 codes (Table 1 in Supplementary Data) for
CHD RE diagnosis (type 2 diabetes, peripheral vascular dis-
ease, stroke, abdominal aortic aneurysm, or transient
ischemic attack) between January 1, 2007 and December
31, 2010 were categorized as the CHD RE cohort. The def-
initions for CHD and CHD RE diagnoses were primarily
based on the ATP III guidelines.20 The date of hospital
admission due to CHD and date of CHD RE diagnosis
were designated as the index date for the CHD and CHD
RE cohorts, respectively. In patients with multiple CHD-
associated hospital admissions or multiple CHD RE diagno-
ses, the date of the first admission or diagnosis was desig-
nated as the index date. Patients needed to be
continuously enrolled during 2 years before the index date
and up to 1 year (CHD cohort) or up to 2 years (CHD RE
cohort) after the index date to be included in the study.
The follow-up period was longer for the CHD RE cohort
to provide adequate time for evaluation of CV events
(Table 2 in Supplementary Data), which was one of the
study outcomes. However, in this study, we have reported
CV events occurring within 1 year in the CHD RE cohort
to be consistent with CV outcomes in the CHD cohort. Pa-
tients were excluded if they had a CHD (CHD cohort),
CHD or CHD RE diagnosis (CHD RE cohort), rhabdomyol-
ysis (ICD-9 code 728.88), or chronic kidney disease (ICD-9
codes 585.x or 403.x or 404.x) any time before index date.
As such, the CHD cohort may consist of patients with CHD
RE conditions; the CHD RE cohort consisted of newly diag-
nosed CHD RE patients without prior CHD.
Study measures
Outcomes evaluated included statin treatment patterns,
LDL-C values, and post-index CV events.
Assessment of outcomes in the CHD cohort
Statin therapy was categorized as low-, moderate-, high-
intensity and fixed-dose combination statins. The catego-
rization by intensity was as per the 2013 ACC/AHA
definition for statins (see Table 3 in Supplementary
Data), and the fixed-dose combinations included simva-
statin with ezetimibe, simvastatin with niacin, and lova-
statin with niacin. Statin therapy was evaluated at
baseline and at 30, 90, and 365 days after the index date.
Baseline statin therapy was defined as the index hospitali-
zation period because all CV events and revascularization
procedures for defining CHD would have occurred during
hospitalization. A pharmacy claim for a statin during hos-
pitalization was included as baseline statin therapy. In pa-
tients with multiple statin claims, the one closest to the
hospital discharge date was considered as baseline statin
therapy. Post-index statin therapy pattern was evaluated
Figure 1 Patient selection flowchart. CHD, coronary heart disease; CHD RE, coronary heart disease risk equivalent; CKD, chronic kidney
disease; CV, cardiovascular.
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to 365 days. The statin claim closest to 30th, 90th, or
365th day was included as post-index statin therapy. The
study did not assess statin initiation or discontinuation
rates, rather a snapshot of statin claims during the
various post-index intervals was evaluated for the CHD
and CHD RE cohorts. The proportion of patients with
LDL-C $ 100 mg/dL was evaluated at 30 days before
the index date and at 30-day intervals up to 1 year after
the index date. Patients were not longitudinally followed
over time, but a cross section of patients with available
LDL-C values was evaluated at each 30-day intervals.
For assessing baseline LDL-C status, a 13-month LDL-C
value capture window (365 days before index date through
30 days after index date) was used, and the value closest
to index date was included. CV events (MI, stroke,
unstable angina, heart failure, revascularizations proce-
dures [coronary artery bypass graft and percutaneous
coronary intervention], and transient ischemic attack)
were evaluated over a 1-year period after index date.Assessment of outcomes in the CHD RE cohort
Statin treatment and lipid values were evaluated
separately for a sub-cohort of patients who experienced
post-index CV events vs those who did not experience a
post-index CV event to observe for differences in these
respective outcomes between the cohorts. For assessment of
statin therapy, baseline was the time period from 90 days
pre-index date to index diagnosis date. In patients with
multiple statin pharmacy claims, the one closest to the
index date was considered as the baseline statin. The
definitions for post-index periods were same as those
used for defining the CHD cohort. Assessment of patients
with LDL-C $ 100 mg/dL and post-index CV events was
the same as that for the CHD cohort.
Statistical analysis
The analysis included means and standard deviations for
continuous variables and counts and percentages for cate-
gorical variables. Baseline demographic variables included
Table 1 Baseline demographic and clinical characteristics
Variable
CHD cohort
(N 5 175,103)
CHD RE sub-cohort
without post-index
CV events (N 5 64,957)
CHD RE sub-cohort with
post-index CV events
(N 5 3333)
Age, mean (SD) 62.6 (13.0) 61.3 (14.6) 64.9 (13.8)
Age , 65 (n, %) 112,694 (64.4) 42,916 (66.1) 1885 (56.6)
Male (n, %) 105,499 (60.2) 31,038 (47.8) 1832 (55.0)
Payer type (n, %)
Preferred provider organizations 87,378 (49.9) 34,532 (53.2) 1697 (50.9)
Health maintenance organizations 23,925 (13.7) 9722 (15.0) 518 (15.5)
Comprehensive insurance 38,341 (21.9) 12,435 (19.1) 771 (23.1)
Other/unknown* 25,459 (14.5) 8268 (12.7) 347 (10.5)
Geographic distribution (n, %)
Northeast 23,734 (13.6) 7460 (11.5) 473 (14.2)
North Central 53,021 (30.3) 18,894 (29.1) 1144 (34.3)
South 64,996 (37.1) 27,388 (42.2) 1223 (36.7)
West 24,661 (14.1) 11,025 (17.0) 481 (14.4)
Unknown 8691 (5.0) 190 (0.3) 12 (0.4)
Patients with available baseline LDL-C values (n, %)† 5329 (3.0) 2017 (3.1) 74 (2.2)
LDL-C, mean (SD) 104.9 (43.5) 109.2 (42.2) 108.8 (48.4)
LDL-C $ 100 mg/dL (n, %) 2816 (52.8) 1205 (59.7) 44 (59.5)
Comorbidities
Type 2 diabetes (n, %) 49,628 (28.3) 0‡ 0‡
Hypertension (n, %) 100,004 (57.1) 31,890 (49.1) 1673 (50.2)
Charlson Comorbidity Index score
Mean (SD) 2.3 (2.3) 1.5 (1.8) 1.7 (1.8)
0 (n, %) 44,477 (25.4) 23,952 (36.87) 1010 (30.30)
1 (n, %) 37,870 (21.6) 15,301 (23.56) 728 (21.84)
2 (n, %) 27,393 (15.6) 9930 (15.29) 588 (17.64)
$3 (n, %) 65,363 (37.3) 15,774 (24.28) 1007 (30.21)
CHD, coronary heart disease; CHD RE, coronary heart disease risk equivalent; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; SD,
standard deviation.
*Other payer types include exclusive provider organization, non-capitated, partially capitated, and capitated point of service, consumer-directed
health plan, and high-deductible health plan. Unknown also includes missing.
†Due to limited availability of LDL-C values, a 13-month window (365 days before index date through 30 days after index date) was used to capture
the LDL-C values, and the one closest to index date was included as baseline LDL-C value.
‡Comorbidities were evaluated over a 1-year time period before index date. As part of CHD RE cohort inclusion criteria, patients have no prior/base-
line type 2 diabetes.
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region, and payer type. Clinical variables included LDL-C
values, diabetes status, hypertension status, and Charlson
Comorbidity Index score. The proportion of patients
receiving statins by intensity (low, moderate, and high)
and as fixed-dose combinations and proportion of patients
with LDL-C $ 100 mg/dL were assessed. The figures for
displaying the proportion of patients also included error
bars to estimate the 95% confidence intervals. Post-index
CV events were evaluated as cumulative incidence rates
using the Kaplan–Meier estimator. All statistical analyses
were performed using SAS 9.2 (SAS institute, Cary, NC).
Results
The final study sample consisted of 175,103 patients in the
CHD cohort and 68,290 patients in the CHD RE cohort(Fig. 1). Of the 68,290 CHD RE patients, 3333 patients had a
CV event during the post-index period, and 64,957 patients
did not have a post-index CV event. Table 1 summarizes
the baseline demographic and clinical characteristics of the
CHD and CHD RE sub-cohorts. Mean age was highest in
the CHD RE sub-cohort with post-index CV events
(64.9 6 13.8 years); CHD cohort had a higher proportion
of patients aged $65 years (64.4%) and more male patients
(60.2%) vs other cohorts. Throughout the study period,
4.1% to 4.5% of the patients had at least 1 LDL-C value re-
corded. Mean baseline LDL-C ranged from
108.8 6 48.4 mg/dL (CHD RE sub-cohort with post-index
CV events) to 104.9 6 43.2 mg/dL (CHD cohort). LDL-C
$ 100 mg/dL at baseline was observed in more than 52%
of patients with available LDL-C measures at baseline.
Mean Charlson Comorbidity Index was highest for CHD
cohort vs the CHD RE sub-cohorts (2.3 vs 1.5 and 1.7).
Unni et al Statins, LDL-C, and CV event assessment 67Statin therapy patterns
Of those patients who were prescribed statins, most had
a pharmacy claim for a moderate-intensity statin followed
by high-intensity statin at the measured time points (Fig. 2).
There was an increase in the proportion of patients pre-
scribed statins at each time period from baseline up to
365 days across all cohorts. Comparatively, a greater pro-
portion of patients in the CHD cohort were prescribed sta-
tins during all measured time points. At the end of 1 year,
approximately 39% of patients in the CHD cohort and 44%Figure 2 Statin therapy patterns. CHD, coronary heart disease; CHDpatients in the CHD RE sub-cohort with post-index CV
events were not prescribed statins.
Patients with LDL-C $ 100 mg/dL
There were respectively 7,162, 2,924, and 137 patients
in the CHD cohort and CHD RE sub-cohorts without and
with post-index CV events that had at least 1 LDL-C value
at 30 days pre-index date through 1-year post-index date.
The number of patients with LDL-C $ 100 mg/dL showed
no clear trend across the measured time periods for allRE, coronary heart disease risk equivalent; CV, cardiovascular.
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in the CHD cohort and CHD RE sub-cohort with post-index
CV events and approximately 46% patients in the CHD RE
sub-cohort without post-index CV events continued to have
an elevated LDL-C value (Fig. 3).Post-index CV events
The most common CV events within 1 year post-index
were MI (4.3%) and heart failure (2.8%) in the CHD cohort
and stroke (6.1%) and heart failure (1.3%) in the CHD RE
cohort (Table 4 in Supplementary Data). There were 9.9%
patients in the CHD cohort and 7.3% patients in the CHD
RE cohort with at least 1 CV event within 1 year post-
index date (Fig 4).Figure 3 Proportion of patients with low-density lipoprotein choleste
coronary heart disease; CHD RE, coronary heart disease risk equivalenDiscussion
The results of this contemporary study aid in the
understanding of statin therapy patterns, LDL-C status,
and CV events in a commercially insured, large national
sample of the US population with high-risk CHD and CHD
RE diagnosis. A key finding in this study was the lack of
statin therapy among 39% of CHD and 61% of CHD RE
patients 91 to 365 days after baseline. This is concerning as
it indicates substantial gaps in statin therapy among high-
risk patients in spite of the overarching support of ATP III
guidelines for statin therapy in these patients. Statin use
was relatively lower from baseline to 90 days post-baseline
vs 91 to 365 days post-baseline. This may be due to patients
receiving a 3-month prescription fill of statins at baseline.
Among patients who were prescribed statins, most of themrol $ 100 mg/dL pre- and post-index date in the 3 cohorts. CHD,
t; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol.
Figure 4 Cumulative incidence rate of post-index CV events for
CHD and CHD RE cohorts. CABG, coronary artery bypass graft;
CHD, coronary heart disease; CHD RE, coronary heart disease
risk equivalent; CV, cardiovascular; PCI, percutaneous coronary
intervention.
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intensity statin at baseline, and this outcome is similar to
that reported by Simpson et al25 who evaluated statin treat-
ment patterns in high-risk patients with CHD, atheroscle-
rotic vascular disease, and diabetes in a payer-specific
population. However, unlike the study by Simpson et al,
more patients in this non-payer-specific database study
were prescribed a high-intensity statin (8.6% vs 2.0%),
and fewer patients were prescribed a low-intensity statin
(1.4% vs 17.0%) at baseline. This may be due to differences
in the identification of the study sample and definition of
statin intensity (Simpson et al study did not use the ACC/
AHA guidelines definition).
An encouraging upward trend was observed for overall
use of moderate- and high-intensity statins from baseline to
end of follow-up. Nevertheless, the use of high-intensity
statins at 1-year follow-up in the CHD cohort was
considerably lower than moderate-intensity statins (17.7%
vs 36.4%) indicating underutilization of high-intensity
statins in most of the high-risk patients. Similar findings
were reported by Rosenson et al26 who evaluated statin use
by intensity using the ACC/AHA guidelines among Medi-
care beneficiaries after CHD events and Rodriguez et al19
who examined use of high-potency statins in ASCVD pa-
tients in a managed care database. A more recent study
by Nguyen et al27 reported that 42% of ASCVD patients
received guideline-recommended high-intensity statins.
However, Nguyen’s study was conducted in a single aca-
demic medical center from January 1, 2013 through
November 11, 2013 vs our study, which evaluated statin
therapy over a 5-year period in a nationally representativedatabase. Thus, our results are consistent with existing
studies, which demonstrated the low use of high-intensity
statins among high-risk CVD patients. Although the rea-
sons associated with the gaps in high-intensity statin utili-
zation and lack of statin use were not assessed, studies
have implicated low rates of patient compliance with sta-
tins25,28 and statin intolerance being reported in 7% to
29% of patients29–31 as potential reasons.
At baseline, more than half of the CHD and CHD RE
patients with available LDL-C measures had LDL-C levels
$ 100 mg/dL. This number dropped considerably during
follow-up and at the end of 1 year, approximately 29% to
46% patients had elevated LDL-C. These results are similar
to those by Jones et al32 who reported 23% to 33% of CHD
and CHD RE patients across 3 data sources with LDL-C $
100 mg/dL after receiving statin therapy for at least
90 days. LDL-C goal attainment has been found to be espe-
cially challenging as reported by Boekholdt et al33 in a
meta-analysis of statin trials where more than 40% of the
trial participants receiving high-dose statins did not achieve
LDL-C goal. This indicates the significant interpatient vari-
ability in LDL-C reduction with a fixed statin dose. As per
the NLA 2015 recommendations for patient-centered man-
agement of dyslipidemia, LDL-C goal attainment is impor-
tant for CV risk management. Our study indicates that even
among high-risk patients, there are many who do not reach
LDL-C goal. Further investigation to understand the under-
lying reasons associated with the lack of LDL-C goal
attainment is warranted.
The cumulative CV incidence rate was higher among
CHD patients, which was expected given the high risk for
subsequent CV events in this patient population.34,35 At the
end of 1 year, at least 9.2% of all patients experienced at
least 1 CV event. Although we did not assess statin therapy
status or LDL-C levels of patients who had CV events dur-
ing follow-up, studies have demonstrated that residual CV
risk remains in high-risk patients despite LDL-C reduc-
tion.18 Therefore, these patients with CV events would
likely benefit from more intensive LDL-C treatment and
monitoring.
Evidence from the large-scale statin meta-analysis
studies5,33 and the recently concluded IMPROVE-IT trial8
has demonstrated a CV outcomes benefit with reductions
in LDL-C. These studies further support that additional
LDL-C lowering is beneficial, and a floor LDL-C value
has not been determined. CHD and CHD RE patients may
require more robust treatment, and our study highlights the
need for better LDL-C management among these patients.
Limitations of the study include its observational nature
using a retrospective claims data source. ICD-9 codes used
to identify and categorize the CHD and CHD RE patients
may have been subjected to errors associated with miscod-
ing of relevant diagnoses. There was no information on
dietary or exercise habits of these patients that might have
been used in addition to statin therapy to control LDL-C
levels. Also, the higher proportion of patients not receiving
statins (39%–61%) and the relatively lower prevalence of
70 Journal of Clinical Lipidology, Vol 10, No 1, February 2016patients with LDL-C $ 100 mg/dL (21%–54%) $ 91 days
after baseline may be attributed to patients paying for their
statins out-of-pocket without going through their insurance
provider and hence not captured in the study database. In
addition, LDL-C values were available in 4.1% to 4.5% of
patients throughout the study period. For patients with
LDL-C values, they were not available longitudinally
across the different time periods. LDL-C value-related
limitations are not unique to our study.36,37 Nevertheless,
this limitation highlights the need for more frequent moni-
toring of LDL-C among high-risk patients. The lack of
detailed clinical information or notes precluded us from
analyzing reasons behind treatment decisions, and we
were unable to ascertain if patients took the prescribed
medication. Additional research should use contemporary
data to further understand the effects of the introduction
of current guidelines and 2015 NLA LDL-C goal of
,70 mg/dL among very high-risk patients.Conclusions
Although statin treatment was observed for most of the
patients at high risk for CVD, 39% to 44% patients had no
statin therapy at the end of 1 year. More than 9.2% of
patients had at least 1 CV event during follow-up. Elevated
LDL-C was observed in 29% to 46% of patients at the end
of 1 year. The high proportion of patients with elevated
LDL-C indicates that there is room for better LDL-C
management among high-risk patients.Financial disclosures
The study was funded by Amgen Inc.
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Description of Truven MarketScan database
The Truven Health MarketScan Research Database
integrate individual-level health (medical, drug), laboratory
results and hospital discharge, and death data into de-
identified data sets. The data are submitted by large
employers, managed care organizations, hospitals, and
Medicare and Medicaid programs.
The Truven MarketScan database offer the largest
convenience sample available in proprietary databases,
with more than 200 million unique patients since 1995
and are large enough to allow creation of a nationally
representative data sample of Americans with employer-
provided health insurance.
The Truven MarketScan Database consists of 3 core
claims databases, the MarketScan Commercial Claims and
Encounters Database, the MarketScan Medicare Supple-
mental and Coordination of Benefits database, and the
MarketScan Medicaid Multi-State database. These data-
bases are described in more detail in the following list.
1. The MarketScan Commercial Claims and Encounters
Database (commercial database) consists of medical
and drug data from employers and health plans for
several million individuals annually, encompassing
employees, their spouses, and dependents who are
covered by employer-sponsored private health insur-
ance. Healthcare for these individuals is provided un-
der a variety of fee-for-service, fully capitated, and
partially capitated health plans including PPOs and
exclusive provider organizations, point of service
(POS) plans, indemnity plans, health maintenance or-
ganization (HMO), and consumer-directed health
plans. Medical claims are linked to outpatient prescrip-
tion drug claims and person-level enrollment informa-
tion. The database is constructed by combining,
standardizing, and enhancing the databases Truven
Health builds on behalf of large employers and health
plans nationwide.
2. The MarketScan Medicare Supplemental and Coordina-
tion of Benefits Database (Medicare Supplemental
Database) is the first in the United States to profile the
health-care experience of retirees with Medicare supple-
mental insurance paid by employers. The database in-
cludes the Medicare-covered portion of payment
(represented as Coordination of Benefits Amount), the
employer-paid portion, and any out-of-pocket patient
expenses. The Medicare Supplemental Database pro-
vides detailed cost, use, and outcomes data for health-
care services performed in both inpatient and outpatient
settings. For most of the population, the medical claims
are linked to outpatient prescription drug claims and
person-level enrollment data through the use of unique
patient or enrollee identifiers.
3. The MarketScan Medicaid Multi-State Database con-
tains the medical, surgical, and prescription drug expe-
rience of more than 36.6 million Medicaid enrollees
from multiple states. It includes records of inpatient ser-
vices, inpatient admissions, outpatient services, and pre-
scription drug claims, and information about long-term
care and other medical care. Data on eligibility (by
month), service, and provider type are also included.
In addition to standard demographic variables, such as
patient age and gender, the database includes variables
of particular value to researchers investigating Medicaid
populations, such as aid category (eg, blind or disabled,
Medicare eligible) and race.
Note: Information on Truven MarketScan database was
based on a white article titled ‘‘Health research data for the
real world: the MarketScan databases’’ published by
Truven Health Analytics in January 2015.
Table 1 ICD-9/CPT codes for identifying CHD and CHD RE cohorts
CHD indication ICD-9/CPT code(s)
Myocardial infarction (MI) 410.xx, 411.0, 412
Unstable angina 411.1
Stable angina 413.xx
Other chronic ischemic heart disease 414.xx
Coronary artery bypass graft (CABG) ICD-9: 36.1x, 3610-3619
CPT: 33510-33536, 33572
Percutaneous coronary intervention (PCI) ICD-9: 066, 3601-3607
CPT: 92973, 92980-92982, 92984, 92995, 92996
CHD RE indication ICD-9/CPT code(s)
Type 2 diabetes (in patients aged $40 y) 250.x0, 250.x2
Peripheral vascular disease 440.xx, 443.9, 443.81
Stroke 430.xx, 431.xx, 432.xx, 433.x1, 434.x1, 997.02, 436
Abdominal aortic aneurism 441.3, 441.6, 441.4, 441.7
Transient ischemic attack 435.xx
CHD, coronary heart disease; CHD RE, coronary heart disease risk equivalent; CPT, Current Procedural Terminology; ICD-9, International Classification
of Diseases, 9th Revision.
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Table 2 ICD-9 codes/CPT codes for identifying CV events/procedures in the post-index period
CV event ICD-9/CPT code(s)
Myocardial infarction (MI)* 410.xx
Stroke 430.xx, 431.xx, 432.xx, 433.x1, 434.x1, 997.02, 436
Unstable angina hospitalization† 411.1
Coronary artery bypass graft (CABG) ICD-9: 36.1x, 3610-3619
CPT: 33510-33536, 33572
Percutaneous coronary intervention (PCI) ICD-9: 066, 3601-3607
CPT: 92973, 92980-92982, 92984, 92995, 92996
Heart failure hospitalization† 428.xx
CPT, Current Procedural Terminology; CV, cardiovascular; ICD-9, International Classification of Diseases, 9th Revision.
*Only new MI diagnosis.
†To confirm that hospitalization was associated with heart failure or unstable angina, we looked for ‘‘in-patient status’’ in the database for a primary
diagnosis of heart failure or unstable angina.
Table 3 Categorization of statins according to 2013 ACC/AHA guidelines22
Low-intensity Statin Moderate-intensity statin High-intensity statin
Fluvastatin 20–40 mg
Lovastatin 20 mg
Pravastatin 10–20 mg
Simvastatin 10 mg
Pitavastatin 1 mg
Fluvastatin 40 mg twice daily
Fluvastatin XL 80 mg
Lovastatin 40 mg
Pravastatin 40 mg and 80 mg
Simvastatin 20–40 mg
Atorvastatin 10 mg and 20 mg
Rosuvastatin 5 mg and 10 mg
Pitavastatin 2–4 mg
Atorvastatin 40–80 mg
Rosuvastatin 20 mg and 40 mg
Simvastatin 80 mg
ACC/AHA, American College of Cardiology/American Heart Association.
Note: Simvastatin 80 mg was not included in this categorization by the guidelines because initiation with this strength or titration to this strength is
not recommended by the Food and Drug Administration due to the increased risk of myopathy, including rhabdomyolysis. However, in this study, we have
categorized simvastatin 80 mg as a high-intensity statin.
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Table 4 Patients with post-index CV events within 1 year in the CHD and CHD RE cohorts
Type of CV event
Post-index events
CHD cohort (N 5 175,103) CHD RE cohort (N 5 68,290)
Number of patients % Number of patients %
Myocardial infarction 7505 4.3 486 0.7
Stroke 2055 1.2 4135 6.1
Unstable angina 3535 2.0 168 0.2
Revascularization (CABG and PCI) 3344 1.9 282 0.4
Heart failure 4983 2.8 872 1.3
Transient ischemic attack 440 0.3 619 0.9
Patients with at least 1 CV event 17,349 9.9 4965 7.3
CABG, coronary artery bypass graft; CHD, coronary heart disease; CHD RE, coronary heart disease risk equivalent; CV, cardiovascular; PCI, percutaneous
coronary intervention.
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